Radiotherapy for oligometastatic tumor improved the prognosis of patients with non-small cell lung cancer (NSCLC)

Hong-Yun Gong, Yi Wang, Guang Han, Qi-Bin Song, Hong-Yun Gong, Yi Wang, Guang Han, Qi-Bin Song

Abstract

Background: This study was conducted to investigate if radiotherapy improved the overall survival (OS) of patients with oligometastatic non-small cell lung cancer (NSCLC).

Methods: From January 2012 to August 2015, 323 NSCLC patients with distant metastasis were administered radiotherapy. Ninety-five patients with oligometastatic NSCLC who were sensitive to the initial chemotherapy were treated with radiotherapy for the residual lesions. Initial treatment consisted of four to six cycles of induction chemotherapy. If the patients responded to the initial treatment without developing new metastases, the residual sites were radiated at a total dose of 56-66 Gy, including the primary and metastatic sites. OS, progression-free survival, and sites of progression were assessed. The Kaplan-Meier method was used to estimate the OS and progression-free survival probabilities.

Results: The median survival of the whole cohort was 15 months (95% confidence interval 6-40) and the median time to progression was 11 months (95% confidence interval 4-24). Sixty-seven patients had died by the end of follow-up. The one-year and two-year OS rates were 58% and 23%, respectively. Patients progressed either with brain (n = 14), bone (n = 11), lung (n = 10), liver (n = 7), adrenal gland (n = 5), or seven other sites of metastases (n = 3). Acute grade III esophageal toxicity was observed in 17 patients (18%) and grade III pulmonary toxicity in seven patients (7%).

Conclusion: Oligometastatic non-progressive NSCLC patients may benefit from aggressive radiotherapy to the residual lesions with acceptable toxicity after systemic chemotherapy.

Keywords: Non-small cell lung cancer; oligometastasis; radiotherapy.

© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Figures

Figure 1
Figure 1
Kaplan–Meier survival estimates from the date of treatment initiation.

References

    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975‐2011, National Cancer Institute, 2014. [Cited 2011.] Available from URL: .
    1. Grossi F, Kubota K, Cappuzzo F et al. Future scenarios for the treatment of advanced non‐small cell lung cancer: Focus on taxane‐containing regimens. Oncologist 2010; 15: 1102–12.
    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8–10.
    1. Plönes T, Dango S, Brugger W, Ludwig C, Stoelben E. Potentially curative surgical therapy in oligometastatic non‐small cell lung cancer. Dtsch Med Wochenschr 2014. Mar; 139 (11): 538–42.
    1. Pfannschmidt J, Dienemann H. Surgical treatment of oligometastatic non‐small cell lung cancer. Lung Cancer 2010; 69: 251–8.
    1. Pastorino U, Buyse M, Friedel G et al. Longterm results of lung metastasectomy: Prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997; 113: 37–49.
    1. Kang X, Chen K. [The conceptual oligometastatic non‐small cell lung cancer and therapeutic strategies]. Zhongguo Fei Ai Za Zhi 2012;15(4):242–5. (In Chinese.)
    1. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non‐small cell lung cancer? A systematic review of the literature. Lung Cancer 2013; 82: 197–203.
    1. Hasselle MD, Haraf DJ, Rusthoven KE et al. Hypofractionated image‐guided radiation therapy for patients with limited volume metastatic non‐small cell lung cancer. J Thorac Oncol 2012; 7 (2): 376–81.
    1. Parikh RB, Cronin AM, Kozono DE et al. Definitive primary therapy in patients presenting with oligometastatic non‐small cell lung cancer. Int J Radiat Oncol Biol Phys 2014; 89 (4): 880–7.
    1. Collen C, Christian N, Schallier D et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall‐cell lung cancer patients. Ann Oncol 2014; 25: 1954–9.
    1. Hu C, Chang EL, Hassenbusch SJ 3rd et al. Non‐small cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 2006; 106: 1998–2004.
    1. Palma D, Haasbeek CJ, Rodrigues G et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR‐COMET): Study protocol for a randomized phase II trial. BMC Cancer 2012; 12: 305.
    1. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: A systematic review of published series. Ann Thorac Surg 2007; 84 (1): 324–38.
    1. Carey Sampson M, Katz A, Constine LS. Stereotactic body radiation therapy for extracranial oligometastases: Does the sword have a double edge? Semin Radiat Oncol 2006; 16 (2): 67–76.
    1. Lopez Guerra JL, Wei Q, Yuan X et al. Functional promoter rs2868371 variant of HSPB1 associates with radiation‐induced esophageal toxicity in patients with non‐small‐cell lung cancer treated with radio(chemo)therapy. Radiother Oncol 2011; 101: 271–7.
    1. Yuan X, Liao Z, Liu Z et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non‐small‐cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009; 27: 3370–8.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel